## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($325.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. How to listen to Elevance Healthâ€™s 2025 earnings call live**
- Source: Stock Titan | 20251222T213224 | Neutral | Relevance: 100%
- Elevance Health (NYSE: ELV) will release its fourth quarter and full-year 2025 financial results on January 28, 2026, at 6:00 a.m. EST, followed by a conference call at 8:30 a.m. EST. Investors can access the call via phone or live webcast, with a replay available until February 27, 2026. The company provides details for both domestic and international access to the earnings call and webcast.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Shareholders to Learn More About the Investigation**
- Source: WREG.com | 20251221T190812 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV) and its officers and directors. The firm is encouraging shareholders who purchased Elevance securities before April 18, 2024, and still hold them, to join the investigation. Investors can find more information and assist the probe by visiting bgandg.com/ELV or contacting the firm directly.

**3. Is Elevance Health Stock Outperforming the Nasdaq?**
- Source: MSN | 20251220T170824 | Neutral | Relevance: 100%
- This article analyzes whether Elevance Health (ELV) stock is currently outperforming the Nasdaq. It likely compares key performance indicators and recent market trends for both to determine ELV's relative strength in the current market environment.

**4. Is Elevance Health Stock Outperforming the Nasdaq?**
- Source: MSN | 20251220T160800 | Neutral | Relevance: 100%
- This article analyzes whether Elevance Health (ELV) stock is currently outperforming the Nasdaq. It likely compares ELV's recent performance metrics against the broader Nasdaq index to assess its market position. The content is missing, so a detailed summary of its findings is not possible.

**5. Signal Advisors Wealth LLC Has $2.08 Million Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251220T130748 | Bullish | Relevance: 100%
- Signal Advisors Wealth LLC significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) during Q3, now holding 6,429 shares valued at approximately $2.08 million. The company reported strong Q3 earnings, surpassing analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $396.21.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $77.5B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.8 |
| Current P/E | 11.5 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.1% to -1.7% (-5.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 54. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.73% (CS: 22) | Neutral |
| RSI_14 | 54.4 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 0.967x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $344.33
- **Stop Loss:** $325.07 (5.6% risk)
- **Target:** $363.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $21,348.46
- **Portfolio %:** 21.35%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*